» Sign in / Register


Zidovudine monophosphate, Sodium Salt

3'-Azido-2',3'-dideoxythymidine-5'-monophosphate, Sodium salt

Cat. No. Amount Price (EUR) Buy / Note
NU-1601S 20 μl (10 mM)150,10 Add to Basket/Quote Add to Notepad
NU-1601L 5 x 20 μl (10 mM)439,50 Add to Basket/Quote Add to Notepad
Structural formula of AzTMP (Zidovudine monophosphate, Sodium Salt, 3'-Azido-2',3'-dideoxythymidine-5'-monophosphate, Sodium salt)
Structural formula of AzTMP

For general laboratory use.

Shipping: shipped on gel packs

Storage Conditions: store at -20 °C
Short term exposure (up to 1 week cumulative) to ambient temperature possible.

Shelf Life: 12 months after date of delivery

Molecular Formula: C10H14N5O7P (free acid)

Molecular Weight: 347.22 g/mol (free acid)

Exact Mass: 347.06 g/mol (free acid)

CAS#: 29706-85-2

Purity: ≥ 95 % (HPLC)

Form: solution in water

Color: colorless to slightly yellow

Concentration: 10 mM - 11 mM

pH: 7.5 ±0.5

Spectroscopic Properties: λmax 267 nm, ε 10.9 L mmol-1 cm-1 (Tris-HCl pH 7.5)

BIOZ Product Citations:

Selected References:
Coulier et al. (2008) Simultaneous determination of endogenous deoxynucleotides and phosphorylated nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cells using ion-pair liquid chromatography coupled to mass spectrometry. Proteomics Clin. Appl. 2:1557.
Cruchaga et al. (2005) Inhibition of Phosphorolysis Catalyzed by HIV-1 Reverse Transcriptase Is Responsible for the Synergy Found in Combinations of 3'-Azido-3'-deoxythymidine with Nonnucleoside Inhibitors Biochemistry 44 (9):3535.
Sarafianos et al. (2002) Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J. 21:6614.
Chenal-Francisque et al. (1999) The highly similar TMP kinases of Yersinia pestis and Escherichia coli differ markedly in their AZTMP phosphorylating activity. Eur. J. Biochem. 265:112.
Rigourd et al. (2000) Inhibition of the initiation of HIV-1 reverse transcription by 3'-azido-3'-deoxythymidine. Comparison with elongation. J. Biol. Chem. 275:26944.
Brundiers et al. (1999) Modifying human thymidylate kinase to potentiate azidothymidine activation. J. Biol. Chem. 274:35289.
Canard et al. (1998) Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer. J. Biol. Chem. 273:14596.
Yan et al. (1995) 3'-Azidothymidine (zidovudine) inhibits glycosylation and dramatically alters glycosphingolipid synthesis in whole cells at clinically relevant concentrations. J. Biol. Chem. 270:22836.
Jaju et al. (1995) Human immunodeficiency virus type 1 reverse transcriptase. 3'-Azidodeoxythymidine 5'-triphosphate inhibition indicates two-step binding for template-primer. J. Biol. Chem. 270:9740.
Tornevik et al. (1995) Cytotoxicity of 3'-azido-3'-deoxythymidine correlates with 3'-azidothymidine-5'-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3'-azidothymidine-5'-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem. Pharmacol. 49:829.
Reardon et al. (1994) Reduction of 3'-azido-3'-deoxythymidine (AZT) and AZT nucleotides by thiols. Kinetics and product identification. J. Biol. Chem. 2269:15999.
Hall et al. (1994) 3'-Azido-3'-deoxythymidine potently inhibits protein glycosylation. A novel mechanism for AZT cytotoxicity. J. Biol. Chem. 269:14355.